Abstract

Background and Aims: Prophylactic administration of platelets and fresh frozen plasma (FFP) is recommended in cirrhotic patients with low platelets/prolonged INR and esophageal varices (EV) that are submitted to endoscopic band ligation (EBL); however it is unknown if this measure prevents post-EBL bleeding. In this analysis we evaluated the outcome of patients undergoing EBL and the role of pre-procedure administration of blood products in this setting. Methods: Retrospective analysis of consecutive EBL procedures in patients with cirrhosis and EV performed at Hospital Clinic, Barcelona from 2010 to 2013. FFP and platelet transfusion were administered if INR was >1.5 and/or platelet count <50×109/L. Complications related to post-EBL bleeding and the relationship with administered blood products were recorded. Results: 516 EBL procedures were performed in 231 patients (70% male), etiology: HCV and alcohol (77%), median MELD 12, Child A/B/C (40/45/15%). EBL procedures were performed for primary (127, 25%) or secondary (290, 55%) prophylaxis and for acute variceal bleeding (AVB) (99, 20%). Median procedure per patient was 2 (1–3). Bleeding occurred in 25 procedures (4.8%). Bleeding complications were not different between Child A/B vs. Child C patients (p = 0.5) and occurred independently of cut-off values and FFP/platelet transfusion (Table 1). FFP and platelets were given in 41 (7.9%) and 39 (7.6%) procedures respectively. Multivariate analysis showed that MELD score (OR, 1.1; 95%CI, 1.0–1.2; p < 0.01) and AVB (OR, 3.4; 95%CI, 1.6–7.0;p < 0.01) emerged as a predictive factors for post-EVL bleeding. Conclusions: Pre-procedure administration of FFP and platelets in cirrhotic patients undergoing EBL does not confer a benefit as a prophylactic measure of post-EBL bleeding. Post-EBL bleeding is independent of pre-procedure cut-off values and FFP/platelet administration. MELD score and AVB are risk factors for post-EBL bleeding. Prospective studies are needed to determine the role of routine administration of blood products prior to EBL in patients with cirrhosis.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.